WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Bruce Keyt Biography and Net Worth

Insider of IGM Biosciences

Dr. Keyt has served as our Chief Scientific Officer since 2012, after serving in that role as a consultant for us beginning in 2010. Prior to joining us, Dr. Keyt served as Chief Technology Officer at Trellis Bioscience, an antibody discovery company, from 2007 to 2010. Previously, he served as Head of Research for Abmaxis, a biotechnology company, from 2005 through its acquisition by Merck in 2006. He was also Vice President of Preclinical Development at Abgenix, a biotechnology company, from 2001 through its acquisition by Amgen in 2005. Dr. Keyt was the Director of Pharmacology at Millennium Pharmaceuticals from 1998 to 2001. From 1982 to 1998, he served in various research and leadership roles at Roche/Genentech, where he made significant contributions to the discovery and development of Avastin, Lucentis, Activase tPA, TNKase-tPA and Kogenate (Factor VIII). Dr. Keyt received a B.A. in Chemistry from Washington University in St. Louis and a Ph.D. in Biochemistry and Pharmacology from Tufts University School of Medicine.

What is Bruce Keyt's net worth?: The estimated net worth of Bruce Keyt is at least $893,901.90 as of December 13th, 2023. Dr. Keyt owns 129,551 shares of IGM Biosciences stock worth more than $893,902 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Keyt may own. Additionally, Dr. Keyt receives an annual salary of $692,950.00 as Insider at IGM Biosciences. Learn More about Bruce Keyt's net worth.
How old is Bruce Keyt?: Dr. Keyt is currently 70 years old. There are 6 older executives and no younger executives at IGM Biosciences. The oldest executive at IGM Biosciences is Mr. Fred M. Schwarzer J.D., CEO, President & Director, who is 71 years old. Learn More on Bruce Keyt's age.
What is Bruce Keyt's salary?: As the Insider of IGM Biosciences, Inc., Dr. Keyt earns $692,950.00 per year. There are 2 executives that earn more than Dr. Keyt. The highest earning executive at IGM Biosciences is Mr. Fred M. Schwarzer J.D., CEO, President & Director, who commands a salary of $977,660.00 per year. Learn More on Bruce Keyt's salary.
How do I contact Bruce Keyt?: The corporate mailing address for Dr. Keyt and other IGM Biosciences executives is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. IGM Biosciences can also be reached via phone at 650-965-7873. Learn More on Bruce Keyt's contact information.
Has Bruce Keyt been buying or selling shares of IGM Biosciences?: Bruce Keyt has not been actively trading shares of IGM Biosciences during the past quarter. Most recently, Bruce Keyt sold 7,574 shares of the business's stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $5.78, for a transaction totalling $43,777.72. Following the completion of the sale, the insider now directly owns 129,551 shares of the company's stock, valued at $748,804.78. Learn More on Bruce Keyt's trading history.
Who are IGM Biosciences' active insiders?: IGM Biosciences' insider roster includes Daniel Chen (Insider), Julie Hambleton (Director), and Bruce Keyt (Insider). Learn More on IGM Biosciences' active insiders.
Are insiders buying or selling shares of IGM Biosciences?: During the last twelve months, IGM Biosciences insiders bought shares 2 times. They purchased a total of 367,473 shares worth more than $3,167,890.26. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 37,701 shares worth more than $424,907.54. The most recent insider tranaction occured on December, 16th when insider Steven Weber sold 539 shares worth more than $4,031.72. Insiders at IGM Biosciences own 57.0% of the company. Learn More about insider trades at IGM Biosciences.
Information on this page was last updated on 12/16/2024.

Bruce Keyt Insider Trading History at IGM Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/13/2023	Sell	7,574	$5.78	$43,777.72	129,551
11/27/2023	Sell	933	$5.06	$4,720.98	137,125
10/4/2022	Sell	25,000	$22.84	$571,000.00	39,489
9/8/2022	Sell	10,000	$19.78	$197,800.00	39,489
9/6/2022	Sell	5,000	$19.06	$95,300.00	39,489
8/22/2022	Sell	6,300	$20.71	$130,473.00	39,489
8/19/2022	Sell	8,700	$22.82	$198,534.00	39,489
4/6/2022	Sell	2,500	$25.00	$62,500.00	40,015
3/30/2022	Sell	7,500	$28.50	$213,750.00
11/2/2021	Sell	1,326	$51.37	$68,116.62
10/5/2021	Sell	1,242	$64.10	$79,612.20
9/3/2021	Sell	1,244	$70.69	$87,938.36	5,557
8/4/2021	Sell	1,242	$67.00	$83,214.00
7/6/2021	Sell	1,247	$82.50	$102,877.50
6/2/2021	Sell	1,245	$79.15	$98,541.75	5,557
5/5/2021	Sell	1,243	$62.50	$77,687.50	5,269
4/6/2021	Sell	1,254	$82.00	$102,828.00	5,269
3/2/2021	Sell	1,619	$90.25	$146,114.75	5,269
2/3/2021	Sell	1,619	$96.00	$155,424.00	5,269
1/4/2021	Sell	883	$88.07	$77,765.81	5,269
12/17/2020	Sell	1,618	$86.10	$139,309.80	5,269
9/10/2020	Sell	1,000	$60.00	$60,000.00	2,637

Bruce Keyt Buying and Selling Activity at IGM Biosciences

IGM Biosciences Company Overview

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Today's Range

Now: $6.90

$6.76

$7.50

50 Day Range

MA: $12.06

$6.90

$17.83

2 Week Range

Now: $6.90

$6.17

$22.50

Volume

434,862 shs

Average Volume

301,638 shs

Market Capitalization

$410.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.08

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad

Take these 4 steps today to protect your retirement NOW

Bruce Keyt Biography and Net Worth

What is Bruce Keyt's net worth?

How old is Bruce Keyt?

What is Bruce Keyt's salary?

How do I contact Bruce Keyt?

Has Bruce Keyt been buying or selling shares of IGM Biosciences?

Who are IGM Biosciences' active insiders?

Are insiders buying or selling shares of IGM Biosciences?